Unternehmens-Profil
Johnson & Johnson is a holding company engaged in the research, development, manufacture, and sale of healthcare products worldwide. It operates through two primary segments: Innovative Medicine, focusing on pharmaceuticals in oncology, immunology, neuroscience, and other therapeutic areas, and MedTech, encompassing medical devices in cardiovascular, orthopaedics, vision care, and electrophysiology. Key products include DARZALEX for oncology, TREMFYA for immunology, and innovative platforms like OMNYPULSE for pulsed-field ablation treatments. Founded in 1887 and headquartered in New Brunswick, New Jersey, the company employs approximately 139,800 people and generates substantial revenue, reaching $94.2 billion in the latest full year with operational growth of 5.3%, driven by a robust pipeline and R&D investments exceeding $32 billion. Johnson & Johnson maintains strong financials, including a dividend yield around 2.1% and consistent payout growth, positioning it as a Dividend King in the healthcare sector. Its diversified portfolio ensures stable cash flows, supporting global distribution through hospitals, physicians, clinics, and partners, while addressing major health challenges across consumer, business, and institutional markets.
Bewertungs-Kennzahlen
Allgemeine Finanzkennzahlen
Chart · 90 Tage
Letzter Kurs: 222,5 USD· Stand 07.05.2026
News · Johnson & Johnson
- 3 Unstoppable Dividend King Stocks to Buy Right Now for Less Than $550
- Warren Buffett and Berkshire Hathaway Own 2 Dividend Kings That Will Never Be Sold
- Darzalex, Erleada & New Drugs Keep J&J's Oncology Engine Charged in Q1
- This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J
- Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission